Replimune Group Stock Investor Sentiment

REPL Stock  USD 14.08  0.03  0.21%   
About 60% of all Replimune's institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Replimune Group suggests that some traders are interested. Replimune's investing sentiment shows overall attitude of investors towards Replimune Group.
  

Replimune Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Replimune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at www.macroaxis.com         
Replimune exotic insider transaction detected
Macroaxis News
over six months ago at news.google.com         
Swiss National Bank Sells 00 Shares of Replimune Group, Inc. - AmericanBankingNEWS
Google News at Macroaxis
over six months ago at zacks.com         
Wall Street Analysts See a 70.57 percent Upside in Replimune Group, Inc. Can the Stock Really Move T...
zacks News
over six months ago at finance.yahoo.com         
Wall Street Analysts See a 70.57 percent Upside in Replimune Group, Inc. Can the Stock Really Move T...
Yahoo News
over six months ago at thelincolnianonline.com         
FY2024 EPS Estimates for Replimune Group, Inc. Raised by Analyst
news
over six months ago at thelincolnianonline.com         
Replimune Group versus INmune Bio Financial Review
news
over six months ago at news.google.com         
Replimune Group, Inc. Holdings Decreased by Lord Abbett CO. LLC - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Replimune Group, Inc. Expected to Post Q3 2025 Earnings of Per Share - MarketBeat
Google News at Macroaxis
over six months ago at seekingalpha.com         
Replimune Group GAAP EPS of -0.77 beats by 0.16
seekingalpha News
over six months ago at finance.yahoo.com         
Replimune Group Inc Reports Fiscal Q3 2024 Results and Extends Cash Runway
Yahoo News
over six months ago at finance.yahoo.com         
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Yahoo News
over six months ago at simplywall.st         
Replimune Group Has Debt But No Earnings Should You Worry?
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Replimune The Fall Is Justified, As Virus Therapy Fails Again In Cancer - Seeking Alpha
Google News at Macroaxis
over six months ago at news.google.com         
How to Take Advantage of moves in - Stock Traders Daily
Google News at Macroaxis
over six months ago at news.google.com         
TD Asset Management Inc Boosts Stake in Replimune Group, Inc. - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Replimune that are available to investors today. That information is available publicly through Replimune media outlets and privately through word of mouth or via Replimune internal channels. However, regardless of the origin, that massive amount of Replimune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Replimune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Replimune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Replimune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Replimune alpha.

Replimune Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 5255 shares by Christopher Sarchi of Replimune at 10.92 subject to Rule 16b-3
09/20/2024
2
Acquisition by Christopher Sarchi of 66675 shares of Replimune at 7.73 subject to Rule 16b-3
10/04/2024
3
Replimune Announces Inducement Grants Under NasdaqListing Rule 5635
10/09/2024
4
Acquisition by Jean Franchi of 67500 shares of Replimune at 17.66 subject to Rule 16b-3
11/01/2024
5
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635
11/08/2024
6
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
11/12/2024
7
Disposition of 5207 shares by Christopher Sarchi of Replimune at 10.78 subject to Rule 16b-3
11/18/2024
8
Replimunes chief commercial officer sells 56,131 in stock
11/21/2024
9
Replimune stock target lifted, outperform on BLA submission
11/22/2024
10
Replimune Announces Proposed Public Offering
11/25/2024
11
Replimune Announces Pricing of Upsized Public Offering
11/26/2024
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:
Check out Replimune Hype Analysis, Replimune Correlation and Replimune Performance.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Return On Assets
(0.27)
Return On Equity
(0.50)
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.